Northeast Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 83.8646 million yuan, down 35.08% from the same period last year. Total operating revenue was 3.333 billion yuan, down 13.49% year-on-year. Net cash flow from operating activities was negative 73.9632 million yuan, down 170.36% year-on-year. The company's latest asset-liability ratio was 58.37%, gross margin was 32.42%, ROE was 1.52%, and diluted earnings per share was 0.06 yuan.
Northeast Pharmaceutical Group Co LtdNet profit fell 35.08% and revenue declined 13.49% in the interim report.
